Neoplasms

Respiratory Tract (Lung and Bronchial) Diseases

All Conditions

Carcinoma, Non-Small-Cell Lung

Lung Neoplasms

Carcinoma

Respiratory Tract Neoplasms

Thoracic Neoplasms

Lung Diseases

Respiratory Tract Diseases

Carcinoma, Bronchogenic

Bronchial Neoplasms

Antineoplastic Agents

All Drugs and Chemicals

Patritumab deruxtecan

Antineoplastic Agents, Immunological

5.6 mg/kg Q3W \[on Day 1 of each 21-day cycle\]) infused IV over approximately 90 minutes

HER3-DXd

Contact for Program Information

Health Care Professional

Program Team Lead

The purpose of this Medical Access Program is to provide access to HER3-DXd for eligible patients with NSCLC who, in their treating physician's opinion, have an unmet clinical need which cannot be treated with approved and commercially available drugs and who cannot enter a clinical trial prior to commercial availability.

This is a Medical Access Program which will be available to adult patients in the US with metastatic or locally advanced EGFRm NSCLC who have received at least 2 prior systemic therapies, who have no alternative commercially available treatment options, and are not able to enter a clinical trial.

In this Medical Access Program, eligible patients will be treated with HER3-DXd and will continue to receive treatment until any of the following occurs:

* Disease progression
* Unacceptable toxicity
* The benefit-risk no longer favors the individual
* HER3-DXd becomes commercially available in the US and reimbursement is approved for the concerned indication of the Medical Access Program.
* Withdrawal of consent
* Pregnancy
* Physician discretion
* Death

Medical Access Program for Patritumab Deruxtecan

Medical Access Program for Patritumab Deruxtecan (HER3 DXd, U3-1402)

Daiichi Sankyo

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Medical Access Program for Patritumab Deruxtecan	NCT06099639	Epidermal Growt...	HER3-DXd	18 Years -	Daiichi Sankyo
Medical Access Program for Patritumab Deruxtecan	NCT06099639	Epidermal Growt...	HER3-DXd	18 Years -	Daiichi Sankyo

Spots Global Cancer Trial Database for her3 dxd

Every month we try and update this database with for her3 dxd cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Spots Global Cancer Trial Database for her3 dxd

Every month we try and update this database with for her3 dxd cancer trials from around the world to help patients and their families find trials that might be right for them. We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Every month we try and update this database with for her3 dxd cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.